Sunesis Pharmaceuticals - Sunesis 110320
Sunesis provided an update on its ongoing dosing study of vecabrutinib on its 2019 earning conference call: the first response assessment for the...
641 Views
Sunesis Pharmaceuticals - 300mg suggests activity, but higher doses needed
Sunesis reported updated data from the dosing portion of its ongoing Phase Ib/II study of vecabrutinib for chronic lymphocytic leukemia (CLL) and...
1.5k Views
Sunesis Pharmaceuticals - Insight into the future of SNS-510
Sunesis recently presented a poster on the preclinical findings of its PDK1 inhibitor SNS-510. Surprisingly, researchers found that the drug was...
763 Views
Sunesis Pharmaceuticals - On track with vecabrutinib
On the Q118 conference call, Sunesis provided an update of its ongoing vecabrutinib Phase Ib/II trial. The study is continuing to enrol the 50mg...
58 Views
Sunesis Pharmaceuticals - A slight delay
On the YE FY17 conference call, the company provided revised guidance on the dosing portion of its ongoing Phase Ib/II study of vecabrutinib...
32 Views